Houston has some much-needed new lab space in the Texas Medical Center. Photo courtesy of CUBIO

While Houston has been recognized as an emerging hub for life sciences, access to lab space is a huge factor in that equation — and one where the city has room for improvement.

CUBIO Innovation Center, located in the heart of the Texas Medical Center, has witnessed that first hand. First opening as a larger coworking concept, CEO Wesley Okeke says it was the smaller lab space that was booked every day. CUBIO pivoted and redistributed their operations to offer more dry lab space to its tenants. Now, the organization is ready to reach the next stage by introducing a new wet lab that opens doors for biotech innovators who need specific infrastructure, equipment, and environment.

“We have all the necessary equipment for a fully functioning biotech lab,” Okeke tells InnovationMap.

"For those working with cell culture, the dry lab provides almost no resources or infrastructure for you to build it out," he continues. "A wet lab brings in the necessary equipment and environment to be successful in developing pharmaceuticals, drug delivery devices, whatever you need in the biotech space.”

The new space can support 15 early stage biotech startups. Photo courtesy of CUBIO

Most of Houston's wet lab space is housed in academic or health care institutions. Getting into those labs can be competitive and complicated, especially when it comes to intellectual property. CUBIO wanted to offer an alternative for early stage biotech teams working on a tight budget and not looking for a long-term commitment.

“When it comes to finding wet lab space, it’s almost nonexistent," Okeke says. "There are a very few out there, but there are very few considering the ecosystem of biotech research in Houston.”

Okeke says CUBIO has seen interest from out-of-town startups looking for space — and not being able to find it without building it themselves.

"We have created what we call lab offices, which could be individual labs, but we have a main area with all our equipment," he says.

And the new space has room to grow. Right now, CUBIO can support 15 companies in its space. With potential to expand on its current sixth floor and to the fifth floor as well, that could grow to a capacity of 50 companies.

Monthly rent starts at $400 for a workbench and up to $950 for a private office and a workbench in the lab. All of CUBIO's memberships options include incubation support from the team and its network of mentors and experts.

“My personal dream and vision is to help these startups in Houston get what they need — get the resources they need and the support they need to launch," Okeke says.

The CUBIO team offers incubation support for its tenant startups. Photo courtesy of CUBIO

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."